CSIMarket
 
Adaptimmune Therapeutics Plc  (ADAP)
Other Ticker:  
 
 
Price: $1.4800 $0.02 1.370%
Day's High: $1.49 Week Perf: -3.9 %
Day's Low: $ 1.42 30 Day Perf: 15.63 %
Volume (M): 634 52 Wk High: $ 2.05
Volume (M$): $ 938 52 Wk Avg: $0.94
Open: $1.47 52 Wk Low: $0.42



 Market Capitalization (Millions $) 1,873
 Shares Outstanding (Millions) 1,265
 Employees -
 Revenues (TTM) (Millions $) 66
 Net Income (TTM) (Millions $) -114
 Cash Flow (TTM) (Millions $) 37
 Capital Exp. (TTM) (Millions $) 5

Adaptimmune Therapeutics Plc
Adaptimmune Therapeutics Plc is a biopharmaceutical company that specializes in the development of novel, personalized immunotherapies for the treatment of cancer. The company utilizes its T-cell receptor (TCR) platform to engineer T-cells to recognize and target specific cancer cells.

Adaptimmune's approach involves modifying a patient's own T-cells to express a specific TCR that can recognize cancer cells expressing a specific antigen. This personalized immunotherapy approach aims to enhance the body's immune response against cancer while minimizing damage to healthy cells.

The company has multiple clinical-stage programs targeting various types of solid tumors and hematologic malignancies. Their lead product candidate, ADP-A2M4, is currently being evaluated in Phase 2 trials for the treatment of multiple solid tumor types, including synovial sarcoma and head and neck cancer.

Adaptimmune also collaborates with pharmaceutical companies, including GlaxoSmithKline and Astellas Pharma, to further develop and commercialize its immunotherapy technologies. Overall, Adaptimmune Therapeutics Plc is focused on advancing the field of personalized cancer immunotherapy to provide more effective and durable treatments for patients.


   Company Address: 60 Jubilee Avenue, Milton Park Abingdon, Oxfordshire 0
   Company Phone Number: 1235 430000   Stock Exchange / Ticker: NASDAQ ADAP
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Adaptimmune Therapeutics Plc

Financial Struggles Plague Adaptimmune Therapeutics Plc in Q4 2023



Adaptimmune Therapeutics Plc, a leading biotechnology and pharmaceutical company, recently released its financial results for the October to December 31 2023 fiscal span. The company has experienced challenges with decreasing revenue, widening net deficit, and below-average accounts receivable values. Although there have been some positive developments, Adaptimmune Therapeutics Plc continues to face an uphill battle in recovering its financial stability.
Revenue Decline and Continual Losses
During the specified fiscal span, Adaptimmune Therapeutics Plc reported a substantial decline in revenue. The revenue dwindled by an alarming -84.183% to $1.83 million, compared to $11.55 million in the same period a year ago. Even when compared sequentially, the revenue tumbled by -80.703% from $9.47 million.
The company's financial performance exhibited a persistent trend of losses, registering a deficit of $-0.03 per share, similar to the previous year. This trend continued throughout the fiscal period, with Adaptimmune Therapeutics Plc reporting a net deficit of $-47.917 million, significantly higher than the $-29.250 million recorded a year ago.

Adaptimmune Therapeutics Plc

Adaptimmune Therapeutics Reports a Slight Per-Share Shortfall of $0.03 during Q3 2023 Earnings Season



Adaptimmune Therapeutics Plc has witnessed a subtle increase of 0.9% in its stock during the last five trading days. However, the year-to-date performance remains concerning, with a significant decline of -66.47%. Let's delve deeper into the recent financial results and evaluate how they might impact the company's future prospects.
Revenue Growth Amidst Industry Challenges:
In the most recent fiscal period, Adaptimmune Therapeutics Plc reported an impressive surge in revenue of 29.15% to $9.47 million compared to the same quarter of the previous year. This revenue increase is particularly remarkable when compared to the top-line reduction experienced by most of its peers in the Biotechnology & Pharmaceuticals sector during the matching period.
While the revenue growth is encouraging, it is essential to acknowledge that the company has still incurred a loss of $-0.03 per share. However, this loss reflects an improvement from the previous quarter, in which the loss per share was $-0.02.

Adaptimmune Therapeutics Plc

Adaptimmune Therapeutics Reports Promising Revenue Increase but Still Suffers Loss of $0.02 per Share

Adaptimmune Therapeutics Plc, a biotechnology company specializing in cell-based immunotherapies, recently reported its financial results for the period ending June 30, 2023. While the company's revenue showed a promising increase of 13.198% compared to the same period last year, reaching $6.67 million, it still experienced a loss of $0.02 per share.
This loss is a significant improvement from the prior financial reporting period, where Adaptimmune's revenue tumbled by -86.178% to $48.28 million, resulting in a zero earnings per share. In terms of net shortfall, the company reported a loss of $21.389 million in the current period, compared to a deficit of $44.520 million in the previous year's comparable period.
One positive aspect worth noting is the increase in accounts receivable, which indicates rising demand for Adaptimmune's products. The accounts receivables were valued at $3.0 million, representing an increase from the preceding quarter. This demonstrates the company's ability to attract customers and generate future revenue.
Looking ahead, Adaptimmune Therapeutics Plc is expected to release its next financial results on November 7, 2023. Investors and analysts will closely observe these results to assess the company's progress and potential for growth.

Adaptimmune Therapeutics Plc

Adaptimmune Therapeutics Plc Achieves Record-Breaking Revenues of $48.28 Million in First Quarter of 2023

Adaptimmune Therapeutics Plc has reported a balanced position for the first quarter of 2023, with profits hitting $0.00 per share, which is a remarkable improvement over a negative of $0.05 per share from the prior year. Comparatively, the preceding quarter saw a loss of $0.03 per share, indicating a significant positive shift in the performance of the company. Boosting this performance was a massive surge in revenue, which rose by 1133.759% to $48.28 million compared to $3.91 million during the same quarter in the prior year. Sequentially, the company's bank balance doubled from the preceding quarter's revenue of $11.55 million.
Adaptimmune Therapeutics Plc recorded a net profit of $1.036 million in the first quarter of 2023, a significant improvement from the corresponding quarter of the previous year, where the company recorded a net loss of $-50.265 million. An increase in profit margins has further resulted in the net margin rising to 2.15% during this period, and operating margin increasing to 3.43%. Looking forward, the company's financials are expected to be revealed on August 03, 2023.






 

Adaptimmune Therapeutics Plc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Adaptimmune Therapeutics Plc does not provide revenue guidance.

Earnings Outlook
Adaptimmune Therapeutics Plc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com